| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PD.1970100813 |
| P953 | full work available at URL | https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpd.1970100813 |
| https://onlinelibrary.wiley.com/doi/full/10.1002/pd.1970100813 | ||
| P698 | PubMed publication ID | 1702538 |
| P2093 | author name string | R. Osathanondh | |
| G. E. Palomaki | |||
| J. A. Canick | |||
| P2860 | cites work | Maternal serum screening for Down's syndrome in early pregnancy | Q35703368 |
| Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities | Q44259917 | ||
| Second trimester screening for trisomy 21. | Q44558857 | ||
| Chromosomal abnormality rates at amniocentesis and in live-born infants | Q46381824 | ||
| Maternal serum markers in screening for Down syndrome | Q67653965 | ||
| Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels | Q68997423 | ||
| Trisomy 18 and maternal serum and amniotic fluid alpha-fetoprotein | Q69008815 | ||
| Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome | Q70056433 | ||
| An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities | Q72729435 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trisomy | Q844903 |
| P304 | page(s) | 546-548 | |
| P577 | publication date | 1990-08-01 | |
| P1433 | published in | Prenatal Diagnosis | Q15760059 |
| P1476 | title | Prenatal screening for trisomy 18 in the second trimester | |
| P478 | volume | 10 |
| Q35197053 | A maternal serum screen for trisomy 18: an extension of maternal serum screening for Down syndrome |
| Q72095130 | A prospective trial of prenatal screening for Down syndrome by means of maternal serum α-fetoprotein, human chorionic gonadotropin, and unconjugated estriol |
| Q73083992 | A retrospective evaluation of second-trimester serum screening for fetal trisomy 18: experience of two laboratories |
| Q34140689 | Advances in prenatal screening for Down syndrome: I. general principles and second trimester testing |
| Q34615050 | Decisions about amniocentesis by advanced maternal age patients following maternal serum screening may not always correlate clinically with screening results: need for improvement in informed consent process |
| Q71612161 | Detection of fetal Turner syndrome with multiple-marker screening |
| Q72089452 | Elevated maternal serum alpha‐fetoprotein, very low unconjugated oestriol, and very low human chorionic gonadotropin associated with recent fetal death |
| Q77802929 | Endocrine analytes in multiple-marker screening |
| Q33768998 | First trimester screening for aneuploidy: serum biochemical markers |
| Q48872212 | Is genetic amniocentesis warranted when isolated choroid plexus cysts are found? |
| Q74529027 | Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses |
| Q42611040 | Maternal Serum Screening in Ontario Using the Triple Marker Test |
| Q43700631 | Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10-14 weeks |
| Q50860489 | Maternal serum alpha-fetoprotein and dimeric inhibin A detect aneuploidies other than Down syndrome. |
| Q33581878 | Maternal serum screening for neural tube defects and fetal chromosome abnormalities |
| Q74200119 | Maternal serum screening for trisomy 18: assessing different statistical models to optimize detection rates |
| Q41924002 | Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome |
| Q33728117 | Participation in maternal serum screening for Down syndrome, neural tube defects, and trisomy 18 following screen-positive results in a previous pregnancy |
| Q64941387 | Perinatal Screening for Congenital Malformations and Genetic Disorders: Current Status and Future Directions. |
| Q35192037 | Prenatal diagnosis for detection of aneuploidy: the options |
| Q35171691 | Prenatal screening for Down syndrome: current and future methods |
| Q36754874 | Prenatal screening for fetal aneuploidy |
| Q33958921 | Prenatal screening for fetal aneuploidy in singleton pregnancies |
| Q35190677 | Prenatal screening for trisomy 18 with free beta human chorionic gonadotrophin as a marker |
| Q41737319 | Prospective evaluation of prenatal maternal serum screening for trisomy 18. |
| Q46274386 | Prospective intervention trial of a screening protocol to identify fetal trisomy 18 using maternal serum alpha‐fetoprotein, unconjugated oestriol, and human chorionic gonadotropin |
| Q44572511 | Quantitative trace analysis of estriol in human plasma by negative ion chemical ionization gas chromatography-mass spectrometry using a deuterated internal standard. |
| Q35194114 | Rapid prenatal diagnosis of chromosomal aneuploidies by fluorescence in situ hybridization: clinical experience with 4,500 specimens |
| Q44119518 | Reliability of second trimester triple screening for Down syndrome in rhesus-negative women |
| Q52133970 | Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. |
| Q34356065 | Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement |
| Q38542489 | Update and Review: Maternal Serum Screening |
Search more.